• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与高加索人(意大利人)群体相比,非洲(坦桑尼亚)群体浸润性乳腺癌中雄激素受体表达是否存在差异?

Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?

作者信息

Bravaccini Sara, Ravaioli Sara, Amadori Dino, Scarpi Emanuela, Puccetti Maurizio, Rocca Andrea, Tumedei Maria Maddalena, Masalu Nestory, Kahima Jackson, Pangan Akwilina, Faustine Lucas, Farolfi Alberto, Maltoni Roberta, Bonafè Massimiliano, Serra Patrizia, Bronte Giuseppe

机构信息

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Azienda Unità Sanitaria Locale (AUSL) Imola, Imola, Italy.

出版信息

Front Endocrinol (Lausanne). 2018 Mar 29;9:137. doi: 10.3389/fendo.2018.00137. eCollection 2018.

DOI:10.3389/fendo.2018.00137
PMID:29651273
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5885470/
Abstract

PURPOSE

Androgen receptor (AR) has been shown to have prognostic implication on breast cancer (BC). Data on the biological features of African BCs are poor. We decided for the first time to compare AR expression of Tanzanian and Italian BC patients.

PATIENTS AND METHODS

Of the 69 consecutive patients seen at the Bugando Medical Center (Mwanza, Tanzania) from 2003 to 2010, who underwent resection of primary BC evaluable for estrogen receptor, progesterone receptor (PgR), and HER2 only 65 were evaluable for AR by immunohistochemistry. Histopathological assessment and biomolecular determinations were performed at the Cancer Institute of Romagna [Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST)-IRCCS, Meldola, Italy]. Caucasian BC patients were selected from an electronic database and matched (1:2 ratio) for year of diagnosis and age at diagnosis.

RESULTS

The median age of patients at diagnosis was 51 (range 29-83) years for Tanzanian and 53 (range 26-86) years for Italian patients. Tanzanian patients harbored tumors with lower AR expression than Italian patients according to the median percentage of immunopositive tumor cells (30% versus 80%,  < 0.0001) and staining intensity ( = 0.0003). The proportion of AR negative patients was likewise higher among Tanzanian patients as regards both ≥1% and ≥10% cutoffs. AR-positive BCs were higher in luminal A and B tumors and decreased in triple-negative (TN) and HER2-enriched tumors in Tanzanian population.

CONCLUSION

AR loss could represent an unfavorable prognostic marker in the African population. The high frequency of TN tumors with high AR expression could open new perspectives of therapy for population in this low income country.

摘要

目的

雄激素受体(AR)已被证明对乳腺癌(BC)具有预后意义。关于非洲乳腺癌生物学特征的数据较少。我们首次决定比较坦桑尼亚和意大利乳腺癌患者的AR表达情况。

患者与方法

2003年至2010年在布甘多医疗中心(坦桑尼亚姆万扎)连续就诊的69例患者中,接受原发性乳腺癌切除术且仅可评估雌激素受体、孕激素受体(PgR)和HER2的患者,只有65例可通过免疫组织化学评估AR。组织病理学评估和生物分子测定在罗马涅癌症研究所[意大利梅尔多拉肿瘤研究与治疗科学研究所(IRST)-IRCCS]进行。从电子数据库中选择白种人乳腺癌患者,并按诊断年份和诊断时年龄进行匹配(1:2比例)。

结果

坦桑尼亚患者诊断时的中位年龄为51岁(范围29 - 83岁),意大利患者为53岁(范围26 - 86岁)。根据免疫阳性肿瘤细胞的中位百分比(30%对80%,<0.0001)和染色强度(=0.0003),坦桑尼亚患者的肿瘤AR表达低于意大利患者。在≥1%和≥10%的临界值方面,坦桑尼亚患者中AR阴性患者的比例同样更高。在坦桑尼亚人群中,AR阳性乳腺癌在管腔A型和B型肿瘤中较高,在三阴性(TN)和HER2富集型肿瘤中较低。

结论

AR缺失可能是非洲人群中一个不良的预后标志物。高AR表达的TN肿瘤的高频率可能为这个低收入国家的人群开辟新的治疗前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/530d/5885470/97c6aaaa98a2/fendo-09-00137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/530d/5885470/97c6aaaa98a2/fendo-09-00137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/530d/5885470/97c6aaaa98a2/fendo-09-00137-g001.jpg

相似文献

1
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?与高加索人(意大利人)群体相比,非洲(坦桑尼亚)群体浸润性乳腺癌中雄激素受体表达是否存在差异?
Front Endocrinol (Lausanne). 2018 Mar 29;9:137. doi: 10.3389/fendo.2018.00137. eCollection 2018.
2
Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations.高加索人(意大利人)和非洲人(坦桑尼亚人)群体乳腺癌生物学特征的差异。
Breast Cancer Res Treat. 2014 May;145(1):177-83. doi: 10.1007/s10549-014-2903-0.
3
Erratum: Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection.勘误:通过粪便DNA完整性检测评估结直肠癌风险和患病率。
J Vis Exp. 2020 Sep 28(163). doi: 10.3791/6446.
4
Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].对《转移性肾细胞癌患者中评估帕唑帕尼与舒尼替尼治疗偏好的随机、对照、双盲、交叉试验:双鱼座研究》的评论。埃斯库迪尔B、波尔塔C、博诺P、鲍尔斯T、艾森T、斯特恩伯格CN、施温德JE、德乔吉U、帕里克O、霍金斯R、塞万E、内格里耶S、汗S、迪亚兹J、雷杜S、马哈茂德F、切拉D。贝尔纳·埃斯库迪尔,古斯塔夫·鲁西研究所,维勒瑞夫;埃马纽埃尔·塞万,弗朗索瓦·巴克莱斯中心,卡昂;西尔维·内格里耶,里昂贝拉尔癌症中心,法国里昂;卡米洛·波尔塔,圣马泰奥综合医院科学研究所(IRCCS),帕维亚;科拉·N·斯特恩伯格,圣卡米洛·福尔拉尼尼医院,罗马;乌戈·德乔吉,罗曼诺肿瘤研究与治疗科学研究所(IRCCS),梅尔多拉,意大利;佩特里·博诺,赫尔辛基大学中心医院,芬兰赫尔辛基;托马斯·鲍尔斯,巴茨实验癌症医学中心,巴茨癌症研究所,伦敦玛丽女王大学,伦敦;蒂姆·艾森,剑桥大学健康合作伙伴,剑桥;奥米·帕里克,兰开夏郡皇家普雷斯顿医院;罗伯特·霍金斯,英国曼彻斯特克里斯蒂癌症研究中心;萨迪亚·汗、何塞·迪亚兹和费萨尔·马哈茂德,葛兰素史克公司,英国乌克斯布里奇;于尔根·E·施温德,慕尼黑工业大学伊萨尔河右岸医院,德国慕尼黑;苏曼·雷杜,葛兰素史克公司,宾夕法尼亚州科尔盖特维尔;大卫·切拉,西北大学费恩伯格医学院,伊利诺伊州芝加哥。《临床肿瘤学杂志》。2014年5月10日;32(14):1412 - 1418;doi: 10.1200/JCO.2013.50.8267。[2014年3月31日在线发表]
Urol Oncol. 2016 May;34(5):251. doi: 10.1016/j.urolonc.2015.03.015. Epub 2015 Apr 30.
5
Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.雄激素受体在 HER2 阳性、ER/PR 阴性乳腺癌中常表达。
Virchows Arch. 2010 Oct;457(4):467-76. doi: 10.1007/s00428-010-0964-y. Epub 2010 Aug 31.
6
[Analysis of prolactin receptor expression in breast cancer subtypes].[乳腺癌亚型中催乳素受体表达的分析]
Biomed Khim. 2020 Jan;66(1):89-94. doi: 10.18097/PBMC20206601089.
7
Role of androgen receptor expression in early stage ER+/PgR-/HER2- breast cancer.雄激素受体表达在早期雌激素受体阳性/孕激素受体阴性/人表皮生长因子受体2阴性乳腺癌中的作用
Ther Adv Med Oncol. 2020 Sep 17;12:1758835920958355. doi: 10.1177/1758835920958355. eCollection 2020.
8
Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.980例中国乳腺癌患者雄激素受体的表达及其与分子亚型的相关性
Breast Cancer (Auckl). 2012;6:1-8. doi: 10.4137/BCBCR.S8323. Epub 2011 Dec 6.
9
A biomarker study in Peruvian males with breast cancer.一项针对秘鲁男性乳腺癌患者的生物标志物研究。
World J Clin Oncol. 2021 Oct 24;12(10):926-934. doi: 10.5306/wjco.v12.i10.926.
10
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?晚期乳腺癌中的雄激素受体:它对抗雌激素治疗的疗效预测有用吗?
BMC Cancer. 2018 Mar 27;18(1):348. doi: 10.1186/s12885-018-4239-3.

引用本文的文献

1
Do AR and TILs have any association with the efficacy of neoadjuvant treatment for HER2-positive breast cancer?AR和肿瘤浸润淋巴细胞(TILs)与HER2阳性乳腺癌新辅助治疗的疗效有何关联?
Medicine (Baltimore). 2025 Sep 5;104(36):e44364. doi: 10.1097/MD.0000000000044364.
2
Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?三阴性乳腺癌中的雄激素受体状态:它与临床病理特征相关吗?
Breast Cancer (Dove Med Press). 2023 May 11;15:359-371. doi: 10.2147/BCTT.S405719. eCollection 2023.
3
Androgen receptor in breast cancer: The "5W" questions.

本文引用的文献

1
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.恩杂鲁胺治疗雄激素受体表达的三阴性乳腺癌。
J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.
2
Targeting Androgen/Estrogen Receptors Crosstalk in Cancer.靶向癌症中的雄激素/雌激素受体相互作用
Trends Cancer. 2016 Jan;2(1):35-48. doi: 10.1016/j.trecan.2015.12.001. Epub 2015 Dec 31.
3
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.
乳腺癌中的雄激素受体:“5W”问题。
Front Endocrinol (Lausanne). 2022 Aug 30;13:977331. doi: 10.3389/fendo.2022.977331. eCollection 2022.
4
Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy.雄激素受体:预测接受曲妥珠单抗联合帕妥珠单抗新辅助治疗的HER2阳性乳腺癌患者病理完全缓解的新标志物。
J Pers Med. 2022 Feb 11;12(2):261. doi: 10.3390/jpm12020261.
5
Receptor-Defined Breast Cancer in Five East African Countries and Its Implications for Treatment: Systematic Review and Meta-Analysis.五个东非国家受体定义的乳腺癌及其对治疗的影响:系统评价和荟萃分析。
JCO Glob Oncol. 2021 Feb;7:289-301. doi: 10.1200/GO.20.00398.
6
Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.雌激素和雄激素受体抑制剂:抗击 COVID-19 的意外盟友。
Cell Transplant. 2021 Jan-Dec;30:963689721991477. doi: 10.1177/0963689721991477.
7
Breast cancer pathology services in sub-Saharan Africa: a survey within population-based cancer registries.撒哈拉以南非洲的乳腺癌病理服务:基于人群的癌症登记处内的调查。
BMC Health Serv Res. 2020 Oct 2;20(1):912. doi: 10.1186/s12913-020-05752-y.
8
Androgen Receptor in Breast Cancer: From Bench to Bedside.雄激素受体在乳腺癌中的作用:从基础到临床。
Front Endocrinol (Lausanne). 2020 Sep 2;11:573. doi: 10.3389/fendo.2020.00573. eCollection 2020.
9
Distribution and characteristics of androgen receptor (AR) in breast cancer among women in Addis Ababa, Ethiopia: A cross sectional study.在埃塞俄比亚亚的斯亚贝巴的女性乳腺癌中雄激素受体(AR)的分布和特征:一项横断面研究。
PLoS One. 2020 May 6;15(5):e0232519. doi: 10.1371/journal.pone.0232519. eCollection 2020.
10
Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.利用雄激素受体通路激活进行乳腺癌靶向 α 粒子放射免疫治疗。
Clin Cancer Res. 2019 Jan 15;25(2):881-891. doi: 10.1158/1078-0432.CCR-18-1521. Epub 2018 Sep 25.
一项在晚期乳腺癌女性中单独使用恩扎卢胺和联合内分泌治疗的 I/ Ib 期研究。
Clin Cancer Res. 2017 Aug 1;23(15):4046-4054. doi: 10.1158/1078-0432.CCR-16-2339. Epub 2017 Mar 9.
4
Targeting the androgen receptor in triple-negative breast cancer.靶向三阴性乳腺癌中的雄激素受体。
Curr Probl Cancer. 2016 Mar-Aug;40(2-4):141-150. doi: 10.1016/j.currproblcancer.2016.09.004. Epub 2016 Sep 20.
5
Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast.雄激素和雌激素受体作为乳腺导管原位癌预后及潜在预测标志物的作用。
Int J Biol Markers. 2015 Nov 11;30(4):e425-8. doi: 10.5301/jbm.5000163.
6
Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.雄激素受体表达、Ki-67与非转移性、淋巴结阴性、雌激素受体阳性且人表皮生长因子受体2阴性乳腺癌的21基因复发评分之间的关联
J Clin Pathol. 2015 Oct;68(10):839-43. doi: 10.1136/jclinpath-2015-203012. Epub 2015 Jun 15.
7
New approaches for improving outcomes in breast cancer in Europe.欧洲改善乳腺癌治疗效果的新方法。
Breast. 2015 Aug;24(4):321-30. doi: 10.1016/j.breast.2015.03.001. Epub 2015 Mar 31.
8
Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.在三阴性乳腺癌患病率增加的人群中表征乳腺癌:加纳女性中的雄激素受体和醛脱氢酶1表达
Ann Surg Oncol. 2015 Nov;22(12):3831-5. doi: 10.1245/s10434-015-4455-x. Epub 2015 Mar 6.
9
Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients.坦桑尼亚西北部资源匮乏地区的三阴性乳腺癌:52例患者的初步研究
BMC Res Notes. 2014 Jun 26;7:399. doi: 10.1186/1756-0500-7-399.
10
Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations.高加索人(意大利人)和非洲人(坦桑尼亚人)群体乳腺癌生物学特征的差异。
Breast Cancer Res Treat. 2014 May;145(1):177-83. doi: 10.1007/s10549-014-2903-0.